Näytä suppeat kuvailutiedot

dc.contributor.authorPorkka, Noora K.
dc.contributor.authorOlkinuora, Alisa
dc.contributor.authorKuopio, Teijo
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorEldfors, Samuli
dc.contributor.authorAlmusa, Henrikki
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorPeltomäki, Päivi
dc.date.accessioned2020-04-24T09:58:53Z
dc.date.available2020-04-24T09:58:53Z
dc.date.issued2020
dc.identifier.citationPorkka, N. K., Olkinuora, A., Kuopio, T., Ahtiainen, M., Eldfors, S., Almusa, H., Mecklin, J.-P., & Peltomäki, P. (2020). Does breast carcinoma belong to the Lynch syndrome tumor spectrum? : Somatic mutational profiles vs. ovarian and colorectal carcinomas. <i>Oncotarget</i>, <i>11</i>(14), 1244-1256. <a href="https://doi.org/10.18632/oncotarget.27538" target="_blank">https://doi.org/10.18632/oncotarget.27538</a>
dc.identifier.otherCONVID_35267030
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/68672
dc.description.abstractInherited DNA mismatch repair (MMR) defects cause predisposition to colorectal, endometrial, ovarian, and other cancers occurring in Lynch syndrome (LS). It is unsettled whether breast carcinoma belongs to the LS tumor spectrum. We approached this question through somatic mutational analysis of breast carcinomas from LS families, using established LS-spectrum tumors for comparison. Somatic mutational profiles of 578 cancer-relevant genes were determined for LS-breast cancer (LS-BC, n = 20), non-carrier breast cancer (NC-BC, n = 10), LS-ovarian cancer (LS-OC, n = 16), and LS-colorectal cancer (LS-CRC, n = 18) from the National LS Registry of Finland. Microsatellite and MMR protein analysis stratified LS-BCs into MMR-deficient (dMMR, n = 11) and MMR-proficient (pMMR, n = 9) subgroups. All NC-BCs were pMMR and all LS-OCs and LS-CRCs dMMR. All but one dMMR LS-BCs were hypermutated (> 10 non-synonymous mutations/Mb; average 174/Mb per tumor) and the frequency of MMR-deficiency-associated signatures 6, 20, and 26 was comparable to that in LS-OC and LS-CRC. LS-BCs that were pMMR resembled NC-BCs with respect to somatic mutational loads (4/9, 44%, hypermutated with average mutation count 33/Mb vs. 3/10, 30%, hypermutated with average 88 mutations/Mb), whereas mutational signatures shared features of dMMR LS-BC, LS-OC, and LS-CRC. Epigenetic regulatory genes were significantly enriched as mutational targets in LS-BC, LS-OC, and LS-CRC. Many top mutant genes of our LS-BCs have previously been identified as drivers of unselected breast carcinomas. In conclusion, somatic mutational signatures suggest that conventional MMR status of tumor tissues is likely to underestimate the significance of the predisposing MMR defects as contributors to breast tumorigenesis in LS.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherImpact Journals LLC
dc.relation.ispartofseriesOncotarget
dc.rightsCC BY 3.0
dc.subject.otherLynch syndrome
dc.subject.otherbreast carcinoma
dc.subject.otherMSI
dc.subject.otherDNA mismatch repair
dc.subject.othersomatic mutation
dc.titleDoes breast carcinoma belong to the Lynch syndrome tumor spectrum? : Somatic mutational profiles vs. ovarian and colorectal carcinomas
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202004242885
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange1244-1256
dc.relation.issn1949-2553
dc.relation.numberinseries14
dc.relation.volume11
dc.type.versionpublishedVersion
dc.rights.copyright© Porkka et al.
dc.rights.accesslevelopenAccessfi
dc.subject.ysoLynchin oireyhtymä
dc.subject.ysorintasyöpä
dc.subject.ysosyöpätaudit
dc.subject.ysoperinnölliset taudit
dc.subject.ysomutaatiot
dc.subject.ysosyöpägeenit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p23697
jyx.subject.urihttp://www.yso.fi/onto/yso/p20019
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p19997
jyx.subject.urihttp://www.yso.fi/onto/yso/p15346
jyx.subject.urihttp://www.yso.fi/onto/yso/p23580
dc.rights.urlhttps://creativecommons.org/licenses/by/3.0/
dc.relation.doi10.18632/oncotarget.27538
jyx.fundinginformationThis work was supported by Jane and Aatos Erkko Foundation (to P.P. and J.-P.M); the Academy of Finland (grant number 294643 to P.P); the Finnish Cancer Foundation (to N.P, P.P., and J.-P.M); the Sigrid Juselius Foundation (to P.P); the HiLIFE Fellows 2017–2020 (to P.P); K. Albin Johansson Stiftelse (to N.P).
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 3.0
Ellei muuten mainita, aineiston lisenssi on CC BY 3.0